患有二次性巨型变化和严重低血糖症的NICTH,原因是潜在的胰岛素样生长因子-2介导作用
Mahdieh Fatollahzadeh1, Hamid Pajavand2, Mahdis Khazaeli Najafabadi3
1Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Journal of diabetes and metabolic disorders
|September 8, 2025
概括
非岛屿细胞瘤低血糖症 (NICTH) 是一种罕见的疾病,由过度的亲胰岛素样生长因子2引起. 通过手术切除一个肺部质量,一个病人被治愈了.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 医学案例报告 病例报告
背景情况:
- 非岛屿细胞瘤低血糖症 (NICTH) 是一种罕见的副瘤综合征.
- 它的特点是过度分泌亲胰岛素样生长因子2 (proIGF-2),导致低血糖.
- 没有人可以表现出壮症的症状.
研究的目的:
- 报告一个52岁妇女患有NICTH综合征的病例.
- 突出诊断挑战和成功治疗这种罕见的疾病.
主要方法:
- 患者呈现出严重的低血糖和巨状的特征.
- 实验室测试显示IGF1,胰岛素,C-和GH的水平下降.
- 一个肺部质量被确定并通过手术切除.
主要成果:
- 患者患有严重的低血糖症 (血糖42毫克/分升),症状包括心跳缓慢,心和混乱.
- 观察到的是巨状的特征,如粗的面部外观和多颜色.
- 胸切除术后的手术,患者的低血糖症状得到解决.
结论:
- NICTH是一种罕见但可治疗的低血糖症原因.
- 造成瘤的手术切除可以导致症状完全消失.
- 这一案例强调了在低血糖症的差异诊断中考虑神经瘤综合征的重要性.
相关概念视频
Hypoglycemia and Glucagon
839
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
839
Insulin: Dosing Regimen and Adverse Effects
695
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
695
Diabetes Mellitus: Type 2 and Gestational
4.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.4K
Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
Major Hormones and Their Functions
1.7K
Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
1.7K
Glucagon-like Receptor Agonists
854
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
854


